Therapeutic effects of loxiglumide on experimental acute pancreatitis using various models.
We investigated the therapeutic effects of a cholecystokinin A (CCK-A) receptor antagonist, loxiglumide, on various models of experimental pancreatitis. This study shows that loxiglumide ameliorated caerulein-induced acute pancreatitis in mice as previously reported. The effects of loxiglumide on hemorrhagic and necrotizing acute pancreatitis is controversial. This study, however, shows that loxiglumide improves the survival rates in necrotizing acute pancreatitis induced by intraductal injection of taurocholate, followed by caerulein injection. In addition, the administration of loxiglumide improved both the biochemical and pathological changes of edematous acute pancreatitis induced by a closed duodenal loop in rats. It is concluded that the CCK-A receptor antagonist, loxiglumide, has therapeutic and/or prophylactic effects on acute pancreatitis in various models of experimental acute pancreatitis.[1]References
- Therapeutic effects of loxiglumide on experimental acute pancreatitis using various models. Satake, K., Kimura, K., Saito, T. Digestion (1999) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg